The conjugate PSMA-Abi demonstrated a 65% tumor growth inhibition level in the 22Rv1 (PSMA+) xenografts in comparison with 78% inhibition for AbiAc under the effect of a 14-fold oral administration of PSMA-Abi at a single dose of 500 mg/kg (7.0 g/kg total) and AbiAc at a single dose of 200 mg/kg (2.8 g/kg total). This evidence concerns the gene FOLH1 and neoplasm.